Duanjie Hou

This inventor holds 17 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 12 EPO patents, primarily in Organic Compounds. Top assignees: Xenon Pharmaceuticals Inc., Novartis Ag. Active years: 2008-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Duanjie Hou. Retrieved from https://idiyas.com/inventor/duanjie-hou

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 17 (Patent Applications = 3)

% Patents Active = 11.8

CIPO Patents = 2

EPO Patents = 12 (Patent Applications = 10)

Average Co-Inventor Count = 10.9

ph-index = 9

Forward Citations = 195(Granted Patents)

Company Filing History:

16 out of 110

Xenon Pharmaceuticals Inc.

where one patent can have more than one assignee

Years Active: 2008-2015

Loading Chart...

Areas of Expertise:

Organic Compounds

Aminothiazole Derivatives

Spiro-Oxindole Compounds

Therapeutic Agents

Heterocyclic Derivatives

Stearoyl-CoA Desaturase Inhibitors

Combination Therapy

Pyridazine Derivatives

Bicyclic Heterocyclic Derivatives

Pyridazine-Piperazine Compounds

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9187426 - Organic compounds (2015-11-17),

2. 8541457 - Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors (2013-09-24),

3. 8501746 - Organic compounds (2013-08-06),

4. 8466188 - Use of spiro-oxindole compounds as therapeutic agents (2013-06-18),

5. 8318949 - Organic compounds (2012-11-27),

6. 8106087 - Spiro-oxindole compounds and their uses as therapeutic agents (2012-01-31),

7. 8071603 - Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors (2011-12-06),

8. 8049016 - Thiazole derivatives which inhibit stearoyl-CoA desaturase enzymes (2011-11-01),

9. 8026360 - Substituted pyridazines as stearoyl-CoA desaturase inhibitors (2011-09-27),

10. 7951805 - Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase (2011-05-31),

11. 7919484 - Combination therapy (2011-04-05),

12. 7767677 - Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors (2010-08-03),

13. 7754711 - Pyridazine derivatives and their use as therapeutic agents (2010-07-13),

14. 7700641 - Spiro-oxindole compounds and their uses as therapeutic agents (2010-04-20),

15. 7592343 - Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitors (2009-09-22),

Title: Duanjie Hou: Innovator in Organic Compounds

Introduction

Duanjie Hou is a prominent inventor based in Burnaby, Canada. He has made significant contributions to the field of organic compounds, holding a total of 17 patents. His work focuses on developing innovative compounds that have potential applications in pharmaceuticals.

Latest Patents

Among his latest patents, Duanjie has developed heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. This invention includes methods for using these derivatives to influence the enzyme's activity, as well as pharmaceutical compositions that incorporate these compounds. Additionally, he has created aminothiazole derivatives that serve as human stearoyl-CoA desaturase inhibitors. These methods aim to treat SCD-mediated diseases or conditions in mammals, particularly humans, by administering specific compounds defined in his patent.

Career Highlights

Duanjie has worked with notable companies in the pharmaceutical industry, including Xenon Pharmaceuticals Inc. and Novartis AG. His experience in these organizations has allowed him to further his research and development efforts in the field of organic chemistry.

Collaborations

Duanjie has collaborated with esteemed colleagues such as Shaoyi Sun and Rajender Kamboj. Their combined expertise has contributed to the advancement of his innovative projects.

Conclusion

Duanjie Hou's work in organic compounds and his numerous patents highlight his role as a key innovator in the pharmaceutical industry. His contributions continue to pave the way for advancements in medical treatments and therapies.

Profile summary based on public USPTO records.